Friday, January 15, 2021
ADVT 
International

Lilly seeks emergency use of its antibody drug for COVID-19

Darpan News Desk The Canadian Press, 07 Oct, 2020
  • Lilly seeks emergency use of its antibody drug for COVID-19

A drug company says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on early results from a study that suggested the drug reduced symptoms, the amount of virus, hospitalizations and ER visits for patients with mild or moderate COVID-19.

Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.

Its drug is similar to one that President Donald Trump received on Friday from Regeneron Pharmaceuticals Inc. These medicines supply concentrated versions of specific antibodies to help the immune system clear the coronavirus that causes COVID-19. They’re given as a one-time treatment through an IV.

Lilly has already started making one of the two antibodies in its drug, betting that ongoing studies would prove it worthwhile.

It’s not clear if the evidence will be viewed as strong enough for the Food and Drug Administration to grant emergency use authorization, as it has done for the antiviral drug remdesivir.

The results are an interim look at a mid-stage study in which 112 people received the antibodies and 156 got a placebo.

The amount of virus was significantly lower 11 days later in those given the drug -- the main goal of the study. Virus also was lower at earlier time points as well. Symptom scores were better at three days.

About 5.8% of patients given placebo required hospitalization or an emergency room visit versus 0.9% of those given the antibodies.

The company said there were no serious drug-related side effects.

MORE International ARTICLES

A debate the likes of which no one's ever seen

A debate the likes of which no one's ever seen

At the very least, it will surely be an "untraditional" affair, said McKinney, who as director of the university's Political Communication Institute has been studying U.S. presidential debates for much of his career.

A debate the likes of which no one's ever seen

3 accused of creating man cave under Grand Central Terminal

3 accused of creating man cave under Grand Central Terminal

A Metropolitan Transportation Authority investigation found that managers at Metro-North Railroad were unaware of the hideaway beneath Track 114.

3 accused of creating man cave under Grand Central Terminal

Breonna Taylor decision reopens U.S. racial wound

Breonna Taylor decision reopens U.S. racial wound

It's just one more eruption of unrest in a year marked by protests against how Black Americans are treated by police.

Breonna Taylor decision reopens U.S. racial wound

New Year's Eve in Times Square incorporates virtual elements

New Year's Eve in Times Square incorporates virtual elements

A virtual experience will be created to allow people to take part in the countdown to 2021 from wherever they are, organizers said.

New Year's Eve in Times Square incorporates virtual elements

CDC changes, then retracts, its take on coronavirus spread

CDC changes, then retracts, its take on coronavirus spread

Officials at the Centers for Disease Control and Prevention say the virus spreads primarily through small airborne droplets, like those that fly through the air when someone coughs or sneezes.

CDC changes, then retracts, its take on coronavirus spread

CDC drops controversial testing advice that caused backlash

CDC drops controversial testing advice that caused backlash

The CDC now says anyone who has been within 6 feet of an infected person for at least 15 minutes should get a test.

CDC drops controversial testing advice that caused backlash